trial

Biomarkers to Enhance Early Schizophrenia Treatment

NCTId NCT06969755
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 180 (estimated)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2030-07-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
180 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-09-30
Primary completion
2030-07-30
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
AripiprazoleRisperidoneClozapine

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Sites

5 total
Birmingham, United StatesLa Jolla, United StatesBelmont, United StatesGlen Oaks, United StatesToronto, Canada

Facts & assertions

4 sourced
Enrollment
180
Phase
PHASE4
Primary Completion Date
2030-07-30
Status
RECRUITING
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidone
drug
Clozapine
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophenia Disorder
indication